Name | ABAI-30 |
---|
Description | ABAI-30 is a potent and orally active anti-inflammatory agent. ABAI-30 effectively inhibits NO production in lipopolysaccharide (LPS) induced RAW264.7 cells[1]. |
---|---|
Related Catalog | |
In Vitro | In RAW264.7 cells, ABAI-30 (10-40 μM) inhibits the TLR4-pp65 and NLRP3-caspase-1 signaling pathway, thus leading to the downregulation of IL6, IL-1β and TNFα at both transcriptional and translational levels[1]. |
In Vivo | In a dextran sulfate sodium (DSS)-induced colitis mouse model, ABAI-30 (25 mg/kg; oral administration; for 5 days) demonstrates high in vivo anti-inflammatory efficacy without causing obvious toxicity[1]. |
References |
Molecular Formula | C17H13N7O2 |
---|---|
Molecular Weight | 347.33 |